Drug Trial Radar · NCT02065375
RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
109
Actual
Start
Feb 28, 2014
Primary completion
Sep 30, 2014
Study completion Sep 30, 2014
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Feb 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.
Conditions
- Inflammation and Pain Following Ocular Surgery
Interventions
Omaveloxolone Ophthalmic Suspension 1.0%Drug
Omaveloxolone Opthalmic Suspension 0.5%Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absence of Anterior Chamber Cells at Day 15 (Visit 5)Time frame: 15 days after the participant receives the first dose
- Absence of Ocular Pain at Day 4 (Visit 3)Time frame: 4 days after the participant receives the first dose
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Garden Grove, California
Site not named
Fort Myers, Florida
Site not named
Kansas City, Missouri
Site not named
Elizabeth City, North Carolina
Site not named
Austin, Texas
Site not named
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.